Table 1.
Overview of absolute and relative (%) frequency of MRI parameters in EBL, EP, and CNS-PNET NOS
| EBL, n = 22 | EP, n = 22 | CNS-PNET NOS, n = 22 | (a) P 1 vs 2 | (b) P 1 vs 3 | |
|---|---|---|---|---|---|
| Patient age, y, mean (SD) | 2.13 (0.91) | 3.20 (1.62) | 6.11 (4.88) | .022 | .002 |
| Tumor length, CC, cm (SD) | 5.55 (1.71) | 6.03 (2.18) | 3.75 (1.63) | ||
| Length, RL, cm (SD) | 5.25 (2.02) | 5.30 (2.07) | 3.84 (1.89) | ||
| Length, AP, cm (SD) | 5.93 (2.53) | 6.52 (3.17) | 4.34 (2.48) | ||
| Tumor volume, cm3 (SD) | 114.68 (100.63) | 145.52 (128.99) | 50.43 (61.39) | .992 | .028 |
| Edema width, cm (SD) | 0.9 (0.14) | 1.14 (0.64) | 0.96 (0.79) | – | – |
| Sex | 22 | 22 | 22 | .262 | 1.0 |
| Male | 14 (64%) | 8 (36%) | 14 (64%) | ||
| Female | 8 (36%) | 14 (64%) | 8 (36%) | ||
| Localization | 22 | 22 | 22 | 1.00 | .048 (.122**) |
| Ventricle supratentorial | 2 (9%) | 3 (14%) | 0 (0.0%) | ||
| Associated to ventricle, supratentorial | 1 (5%) | 2 (9%) | 0 (0.0%) | ||
| Cortex, frontal | 6 (27%) | 5 (23%) | 7 (32%) | ||
| Cortex parietal | 7 (32%) | 8 (36%) | 2 (9%) | ||
| Cortex, occipital | 0 | 0 | 0 | ||
| Cortex temporal | 0 (0.0%) | 0 (0.0%) | 1 (5%) | ||
| Basal ganglia | 0 (0.0%) | 1 (5%) | 3 (14%) | ||
| Cortex, infratentorial | 1 (5%) | 0 (0.0%) | 0 (0.0%) | ||
| Ventricle, infratentorial | 3 (14%) | 3 (14%) | 0 (0.0%) | ||
| Brainstem | 2 (9%) | 0 (0.0%) | 5 (23%) | ||
| No primary | 0 (0.0%) | 0 (0.0%) | 4 (18%) | ||
| Cysts | 22 | 22 | 18** | .11 | .696 |
| Yes | 11 (50%) | 18 (82%) | 6 (33%) | ||
| No | 11 (50%) | 4 (18%) | 12 (67%) | ||
| Cyst periphery | 22 | 22 | 18 | .001 | 1 |
| Yes | 6 (27%) | 18 (82%) | 5 (28%) | ||
| No | 16 (73%) | 4 (18%) | 13 (72%) | ||
| Cyst size | 11 | 18 | 6 | .042 | .56 |
| Big | 2 (18%) | 12 (67%) | 3 (50%) | ||
| Small | 9 (82%) | 6 (33%) | 3 (50%) | ||
| Intratumoral hemorrhage | 22 | 22 | 18 | .406 | .37 |
| Yes | 17 (77%) | 12 (55%) | 10 (56%) | ||
| No | 5 (23%) | 10 (45%) | 8 (44%) | ||
| Signal homogeneity (in T1WI and T2WI) | 22 | 22 | 18 | .362 | 1 |
| Homogeneous | 2 (9%) | 0 (0.0%) | 0 (0.0%) | ||
| Predominantly homogeneous | 3 (14%) | 8 (36%) | 3 (17%) | ||
| Predominantly inhomogeneous | 9 (41%) | 6 (27%) | 9 (50%) | ||
| Inhomogeneous | 8 (36%) | 8 (36%) | 6 (33%) | ||
| Margin | 22 | 22 | 18 | .001 | .001 |
| Well defined | 19 (86%) | 6 (27%) | 3 (17%) | ||
| Predominantly well defined | 3 (14%) | 10 (45%) | 6 (33%) | ||
| Ill defined | 0 (0.0%) | 6 (27%) | 9 (50%) | ||
| T2 signal | 22 | 22 | 18 | 1 | .172 |
| Hyperintense | 1 (5%) | 1 (5%) | 4 (22%) | ||
| Isointense | 2 (9%) | 4 (18%) | 4 (22%) | ||
| Hypointense | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| All appear | 19 (86%) | 17 (77%) | 10 (56%) | ||
| T2 predominant signal | 22 | 22 | 18 | .032 | .96 |
| Hyperintense | 10 (45%) | 2 (9%) | 9 (50%) | ||
| Isointense | 12 (55%) | 20 (91%) | 8 (44%) | ||
| Hypointense | 0 (0.0%) | 0 (0.0%) | 1 (6%) | ||
| Edema | 22 | 22 | 18 | .002 | .002 |
| Yes | 2 (9%) | 13 (59%) | 11 (61%) | ||
| No | 20 (91%) | 9 (41%) | 7 (39%) | ||
| T1 signal | 22 | 22 | 18 | .096* | 1 |
| Hyperintense | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Isointense | 6 (27%) | 8 (36%) | 5 (28%) | ||
| Hypointense | 9 (41%) | 2 (9%) | 10 (56%) | ||
| All appear | 7 (32%) | 12 (55%) | 3 (17%) | ||
| T1 predominant signal | 22 | 22 | 18 | .02 | 1 |
| Hyperintense | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Isointense | 10 (45%) | 19 (86%) | 8 (44%) | ||
| Hypointense | 12 (55%) | 3 (14%) | 10 (56%) | ||
| CE intensity | 22 | 22 | 18 | .14 | .854 |
| None | 5 (23%) | 1 (5%) | 7 (39%) | ||
| Slight | 6 (27%) | 2 (9%) | 4 (22%) | ||
| Moderate | 8 (36%) | 12 (55%) | 3 (17%) | ||
| Intense | 3 (14%) | 7 (32%) | 4 (22%) | ||
| CE homogeneity | 17 | 21 | 11 | .001 | .01 |
| Homogeneous | 1 (6%) | 2 (10%) | 0 (0.0%) | ||
| Predominantly homogeneous | 13 (76%) | 2 (10%) | 2 (18%) | ||
| Predominantly inhomogeneous | 2 (12%) | 10 (48%) | 2 (18%) | ||
| Inhomogeneous | 1 (6%) | 7 (33%) | 7 (64%) | ||
| CE percent of solid tumor | 17 | 21 | 11 | .001 | .038 |
| 1%–25% | 9 (53%) | 2 (10%) | 3 (27%) | ||
| 26%–50% | 7 (41%) | 0 (0.0%) | 2 (18%) | ||
| 51%–75% | 1 (6%) | 4 (19%) | 1 (9%) | ||
| 76%–100% | 0 (0.0%) | 15 (71%) | 5 (45%) | ||
| Diffusion restriction | 22 | 22 | 18 | .4 | 1 |
| Yes | 14 (64%) | 12 (55%) | 11 (61%) | ||
| No | 0 (0.0%) | 3 (14%) | 1 (6%) | ||
| No DWI available | 8 (36%) | 7 (32%) | 6 (33%) | ||
| Confirmed by ADC | 22 | 22 | 18 | 1 | 1 |
| Yes | 11 (50%) | 10 (45%) | 8 (44%) | ||
| No | 0 (0.0%) | 0 (0.0%) | 1 (6%) | ||
| No ADC available | 11 (50%) | 12 (55%) | 9 (50%) |
Abbreviations: CC, cranio-caudal; RL, right–left; AP, anteroposterior; CE, contrast enhancement; ADC, apparent diffusion coefficient; DWI, diffusion-weighted image.
This table shows P-values after paired comparison of imaging parameters in (a) EBL vs EP and (b) EBL vs CNS-PNET NOS. Note that relative frequencies do not equal 100% in some cases, due to mathematical rounding. Statistically significant differences (P < .05) are in bold print.
*Values with .05<P < .1 after Bonferroni correction are considered to show a strong tendency toward significant results.
**Calculation after exclusion of disseminated disease without known primary tumor.